ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
ASSEMBLY BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.16+0.07 (+0.35%)
Close on Oct 19, 2026
- Market cap
- $380.09M
- P/E (TTM)
- –
- Dividend yield
- –
Assembly Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Market Cap | $410.47M | $197.05M |
| Enterprise Value | $90.07M | $106.56M |
| PS Ratio | 5.48 | 3.93 |
| PB Ratio | 1.34 | 2.14 |
| P/TBV Ratio | 1.34 | 2.46 |
Enterprise value
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| EV / Sales | 1.20 | 2.69 |
Income (trailing twelve months)
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Revenue | $74.85M | $57.94M |
| Operating Income | -$8.80M | -$21.44M |
| Net Income | -$42.00K | -$22.46M |
| EBITDA | -$8.69M | -$16.91M |
Margins
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Operating Margin | -11.8% | -44.5% |
| Profit Margin | -0.06% | -39.2% |
| EBITDA Margin | -11.6% | -31.3% |
| FCF Margin | -51.5% | -8.85% |
Returns
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -0.03% | -53.1% |
| Return on Assets (ROA) | -0.02% | -41.0% |
| Return on Capital Employed (ROCE) | -2.86% | -37.8% |
Growth
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 125.1% | 6.01% |
| Revenue Growth (5Y CAGR) | -1.78% | 6.42% |
Balance sheet
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $320.40M | $62.42M |
| Net Cash (Debt) | $320.40M | $15.68M |
| Net Cash Per Share | $15.74 | $0.65 |
| Equity (Book Value) | $305.65M | $48.79M |
| Book Value Per Share | $15.01 | $1.36 |
| Tangible Book Value | $305.65M | $23.06M |
| Working Capital | $304.53M | $75.77M |
Financial position
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Current Ratio | 13.99 | 3.30 |
| Quick Ratio | 13.70 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$38.48M | -$12.35M |
| Capital Expenditures | -$85.00K | -$1.06M |
| Free Cash Flow | -$38.57M | -$20.28M |
| FCF Per Share | -$1.89 | -$0.41 |
Efficiency
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.36 | 0.38 |
| Revenue Per Employee | $1.03M | $398.96K |
| Profits Per Employee | -$575 | -$732.08K |
| Employee Count | 73 | 73 |
Dividends and yields
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Earnings Yield | -0.01% | -21.2% |
| FCF Yield | -9.40% | -7.64% |
| Buyback Yield | 0.00% | -0.58% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 20,360,600 | 59,128,900 |
| Shares Change (YoY) | 133.1% | 11.1% |
| Shares Change (QoQ) | 24.9% | 0.54% |
| Float | 14,463,900 | 48,744,500 |
| Shares Held by Insiders | 29.0% | 11.8% |
| Shares Held by Institutions | 92.1% | 59.4% |
Scores
| Measure | Assembly Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 7.45 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Assembly Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.